Saniona Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Saniona şirketinin toplam hissedar öz sermayesi SEK6.9M ve toplam borcu SEK39.9M olup, bu da borç-öz sermaye oranını 574.8% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla SEK92.5M ve SEK85.5M dir.

Anahtar bilgiler

574.8%

Borç/özkaynak oranı

SEK 39.86m

Borç

Faiz karşılama oranı	n/a
Nakit	SEK 54.39m
Eşitlik	SEK 6.93m
Toplam yükümlülükler	SEK 85.53m
Toplam varlıklar	SEK 92.46m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 30S 'nin kısa vadeli varlıkları ( SEK74.2M ) kısa vadeli yükümlülüklerini ( SEK17.5M ) aşıyor.

Uzun Vadeli Yükümlülükler: 30S şirketinin kısa vadeli varlıkları ( SEK74.2M ) uzun vadeli yükümlülüklerini ( SEK68.0M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 30S şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: 30S şirketinin borç/öz sermaye oranı son 5 yılda 15.2% seviyesinden 574.8% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: 30S şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: 30S un, serbest nakit akışı her yıl % 13 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

Saniona Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Saniona Initiates SAN711 Biomarker Study

Saniona Receives Regulatory Approval for San711 Biomarker Study

New major risk - Financial position

Second quarter 2024 earnings released: kr0.18 loss per share (vs kr0.34 loss in 2Q 2023)

New major risk - Share price stability

First quarter 2024 earnings released: kr0.08 loss per share (vs kr0.35 loss in 1Q 2023)

Saniona AB (publ) to Report Fiscal Year 2023 Results on Apr 30, 2024

New major risk - Negative shareholders equity

Full year 2023 earnings released: kr1.49 loss per share (vs kr3.93 loss in FY 2022)

Saniona Announces the Selection of Its Proprietary GABAA A5 Negative Allosteric Modulator (NAM) Lead Compound, San2465

Saniona AB (publ) Strengthens Epilepsy Pipeline with Selection of SAN2355 as Clinical Candidate

Third quarter 2023 earnings released: kr0.38 loss per share (vs kr0.28 profit in 3Q 2022)

Saniona AB (publ) to Report Fiscal Year 2024 Results on Feb 27, 2025

Saniona AB (publ), Annual General Meeting, May 29, 2024

Saniona Promotes Kv7 Epilepsy Compound to Candidate Selection Phase

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: kr0.34 loss per share (vs kr1.42 loss in 2Q 2022)

New minor risk - Shareholder dilution

First quarter 2023 earnings released: kr0.35 loss per share (vs kr2.14 loss in 1Q 2022)

Full year 2022 earnings released: kr3.93 loss per share (vs kr6.59 loss in FY 2021)

Saniona AB Appoints Nomination Committee for the Annual General Meeting 2023

Third quarter 2022 earnings released: EPS: kr0.28 (vs kr1.50 loss in 3Q 2021)

Saniona AB (publ) to Report Q1, 2023 Results on May 25, 2023

Insufficient new directors

Saniona AB (publ) Announces Anti-Inflammatory and Anti-Fibrotic Candidate SAN903 Is Ready for Clinical Studies

Second quarter 2022 earnings released: kr1.42 loss per share (vs kr1.67 loss in 2Q 2021)

Saniona Progresses Its Kv7 Epilepsy Program into Lead Optimization

Saniona Reports Positive Top Line Results from the SAN711 Phase 1 Clinical Trial

Insufficient new directors

Saniona’S Preclinical Candidate San903 Shows Robust Dampening of Fibrosis in Chronic Kidney Disease Model

Saniona Provides Update on Ongoing Review of Tesofensine in Mexico

Saniona Appoints Anita Milland as Chief Financial Officer, Effective April 30, 2022

Saniona Announces Voluntary Pause of Phase 2B Clinical Trials of Tesomet for Hypothalamic Obesity and Prader-Willi Syndrome

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Saniona AB (publ) to Report Fiscal Year 2021 Final Results on Apr 29, 2022

Saniona Initiates Multiple Ascending Dose Stage of SAN711 Phase 1 Clinical Trial

Saniona Initiates Phase 2b Clinical Trial of Tesomet for Prader-Willi Syndrome

Third quarter 2021 earnings released: kr1.50 loss per share (vs kr1.24 loss in 3Q 2020)

Second quarter 2021 earnings released: kr1.67 loss per share (vs kr1.24 loss in 2Q 2020)

Saniona Initiates Phase 1 Clinical Trial of SAN711

Saniona to Present Preclinical Data on SAN711 at the 7th Congress of the European Academy of Neurology

First quarter 2021 earnings released: kr1.34 loss per share (vs kr1.47 profit in 1Q 2020)

Full year 2020 earnings released: kr1.79 loss per share (vs kr2.95 loss in FY 2019)

Saniona Receives Feedback from U.S. FDA Providing a Regulatory Path Forward for Tesomet in Hypothalamic Obesity

Saniona Receives U.S. FDA Orphan Drug Designation for Tesomet in Prader-Willi Syndrome

New 90-day low: €1.81

Novartis AG (SWX:NOVN) completed the acquisition of Cadent Therapeutics, Inc. from a group of sellers.

New 90-day low: €1.97

Saniona Announces Management Appointments

Co-Founder recently bought €11k worth of stock

New 90-day low: €2.07

Third quarter 2020 earnings released: kr1.24 loss per share

Third quarter 2020 earnings released: kr1.24 loss per share

Saniona AB (publ) to Report Fiscal Year 2021 Results on Feb 24, 2022

Saniona AB (publ) Appoints Nomination Committee Members

Saniona Reports Positive Topline Results from Tesomet Phase 2 Open-Label Extension Study in Hypothalamic Obesity

New 90-day low: €2.37

Saniona Receives Pre-IND Feedback from FDA on Regulatory Path for Tesomet in Prader-Willi Syndrome (PWS) and Hypothalamic Obesity (HO)

Earnings released

Saniona AB (publ) has completed a Follow-on Equity Offering in the amount of $64.999993 million.

New 90-day high - €3.69

An unknown buyer acquired 3.96% stake in Scandion Oncology A/S (NGM:SCOL) from Saniona AB (publ) (OM:SANION) for for $2.3 million.

New 90-day high - €2.83

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin